Outcomes Of Descemet Membrane Endothelial Keratoplasty (Dmek) In A Third Level Hospital.
Published 2023 - 41st Congress of the ESCRS
Reference: PO0662 | Type: Free paper | DOI: 10.82333/b5t5-z893
Authors: Jose Galvez-Olortegui* 1 , Ekaterina Teslenko 2 , Alba Gonzalez-Corte 2 , Manuel Rodrigues-Vera 2 , Maria Fernandez-Garcia 2 , Marta Alvarez-Coronado 2 , Ana Señaris-Gonzalez 2 , Begoña Baamonde-Arbaiza 2
1Service of Ophthalmology,Hospital Universitario Central de Asturias,Oviedo,Spain;Evidence Based Opthalmology Unit (Oftalmoevidencia),Scientia Clinical and Epidemiological Research Institute,Trujillo,Peru, 2Service of Ophthalmology,Hospital Universitario Central de Asturias,Oviedo,Spain
Purpose
To evaluate the outcomes of Descemet membrane endothelial keratoplasty (DMEK) In a third level hospital.
Setting
Descemet membrane endothelial keratoplasty (DMEK), is the gold standard procedure for the treatment of corneal endothelial diseases such as Fuchs endothelial dystrophy (FED) and bullous keratopathy (BK).
Methods
A Retrospective review of all DMEK performed in a third level hospital, was performed. A total of 230 consecutive eyes that underwent DMEK at our institute since 2017 were assessed. Eyes with at least 2-year follow up were included. Main outcome measures were best-corrected visual acuity (BCVA) at 3 and 6 months postDMEK, and last available BCVA, intraocular pressure (IOP), endothelial cell density (ECD), central corneal thickness (CCT), and postoperative complications (Graft detachment, Rebubbling and Reoperations). Donor data was recollected (age, gender, ECD, and preparation details).
Results
37 eyes (31patients) were available. Mean age was 68,24 years. Most surgeries were performed in 2019 (48.6%), in females (54.1%), 19 surgeries in right eye (51.4X%), and 21 (56.7%%) had surgery in both eyes. 33 (89.2%) surgeries were due to Fuchs endothelial dystrophy. Mean CCT and ECD shifted from 628 and 831 preoperatively to 478.5 and 1192 postoperatively respectively.
Mean BCVA shifted from 0.16 preoperatively, to 0.52 in third month, 0.6 in the sixth month, and 0.66 in the last evaluation. Mean BCVA difference before and after surgery was 0.5. 4 patients (10.8%) had graft detachment (≥1/3 of graft surface area), 5 (13.5%) had rebubbling, and 8 (21.6%) had Re-DMEK.
Conclusions
DMEK is a safe and effective long-term treatment option for corneal endothelial diseases, especially Fuchs endothelial dystrophy.